4. The ethics of “good enough”

That’s what Médecins Sans Frontières / Doctors Without Borders, WHO, and other experts are discussing. The West African Ebola crisis led to a push for accelerated access to treatments, arguing that using a potential therapy with promising results in animal studies is OK during a major public health crisis. Meaning, even if the FDA hasn’t approved it for use in humans, patients should still have access (in some circumstances). MSF’s article in The Journal of Medical Ethics seeks to define these “exceptional circumstances” and the goals of using unproven therapies. This could be a tipping point for research ethics. Good news, since there’s still no approved treatment for Ebola.